These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 3535934

  • 21. [The study landscape for prostate cancer].
    Miller K.
    Urologe A; 2005 Dec; 44(12):1431-4. PubMed ID: 16292461
    [Abstract] [Full Text] [Related]

  • 22. Overcoming bcl-2- and p53-mediated resistance in prostate cancer.
    DiPaola RS, Aisner J.
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):112-6. PubMed ID: 10190792
    [Abstract] [Full Text] [Related]

  • 23. Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer.
    Ryan CJ, Zelefsky MJ, Heller G, Regan K, Leibel SA, Scher HI, Kelly WK.
    Urology; 2004 Jul; 64(1):90-4. PubMed ID: 15245942
    [Abstract] [Full Text] [Related]

  • 24. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer.
    Nakabayashi M, Ling J, Xie W, Regan MM, Oh WK.
    Cancer J; 2007 Jul; 13(2):125-9. PubMed ID: 17476141
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [Treatment for hormone-refractory or relapsing prostatic cancer].
    Hirao Y, Ozono S, Okajima E.
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):418-26. PubMed ID: 8678492
    [Abstract] [Full Text] [Related]

  • 27. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.
    Sava T, Basso U, Porcaro A, Cetto GL.
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ, Dunn RL, Hellerstedt B, Cooney KA, Fardig J, Olson K, Pienta KJ, Smith DC.
    Cancer; 2006 Jun 15; 106(12):2617-23. PubMed ID: 16691618
    [Abstract] [Full Text] [Related]

  • 30. The treatment of hormone refractory prostate cancer.
    Panvichian R, Pienta KJ.
    Compr Ther; 1996 Feb 15; 22(2):81-7. PubMed ID: 8689867
    [No Abstract] [Full Text] [Related]

  • 31. Is chemotherapy ready for clinical use in prostatic cancer patients?
    Jones WG.
    Prog Clin Biol Res; 1988 Feb 15; 269():159-76. PubMed ID: 3293058
    [No Abstract] [Full Text] [Related]

  • 32. How effective is cytotoxic chemotherapy for disseminated prostatic carcinoma?
    Eisenberger MA, Kennedy P, Abrams J.
    Oncology (Williston Park); 1987 Jun 15; 1(4):59-71. PubMed ID: 3079482
    [Abstract] [Full Text] [Related]

  • 33. [Chemotherapy in cancer of the prostate].
    D'Acremont B, Gattegno B, Cohen L, Fiatte P, Lucaks B, Thibault P.
    Ann Urol (Paris); 1990 Jun 15; 24(2):87-95. PubMed ID: 2190532
    [Abstract] [Full Text] [Related]

  • 34. Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762.
    de Voogt HJ, Pavone-Macaluso M, Smith PH, de Pauw M, Suciu S.
    Prog Clin Biol Res; 1988 Jun 15; 260():111-7. PubMed ID: 2966403
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Chemotherapy for endocrine resistant cancer of the prostate.
    Eisenberger MA.
    Prog Clin Biol Res; 1990 Jun 15; 359():155-64; discussion 177-80. PubMed ID: 2284289
    [No Abstract] [Full Text] [Related]

  • 37. [Tumor-oriented anti-cancer agent with estrogen as a carrier].
    Ohsawa N, Yamazaki Z.
    Gan To Kagaku Ryoho; 1988 Apr 15; 15(4 Pt 2-1):1065-71. PubMed ID: 3291767
    [Abstract] [Full Text] [Related]

  • 38. [Chemotherapy for prostate cancer].
    Tsushima T, Kumon H.
    Nihon Rinsho; 2000 Jul 15; 58 Suppl():228-36. PubMed ID: 11022719
    [No Abstract] [Full Text] [Related]

  • 39. Is there a best endocrine management of prostatic carcinoma?
    Robinson MR.
    Prog Clin Biol Res; 1988 Jul 15; 269():147-58. PubMed ID: 2969114
    [No Abstract] [Full Text] [Related]

  • 40. A critical assessment of the role of chemotherapy for endocrine-resistant prostatic carcinoma.
    Eisenberger MA, Bezerdjian L, Kalash S.
    Urol Clin North Am; 1987 Nov 15; 14(4):695-706. PubMed ID: 3314063
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.